1194 results about "Fibroblast" patented technology

The invention relates to the technical field of skin care, in particular to a collagen composition with anti-wrinkle and repairing effects and a preparation method. Comprising 1.5-4.5 parts of mixed collagen, 2.5-5 parts of mixed polypeptide and 4-8 parts of mixed extract, wherein the mixed extract comprises 1-2 parts of centella asiatica extract, 1-2 parts of polygonum cuspidatum root extract, 1-2 parts of bilberry fruit extract and 1-2 parts of bidens pilosa extract; the collagen is directly supplied to the skin to supplement collagen, and is mainly used for repairing the skin structure, increasing the density, elasticity and compactness of the skin and remarkably improving fine wrinkles and looseness; the polypeptide inhibits the expression of MMP-1; the natural plant active ingredients promote the expression of TGF-beta, enhance the activity of fibroblasts, accelerate the synthesis of collagen, prevent excessive oxidation of skin, repair skin inflammation, activate cell energy and delay skin aging.

The invention discloses application of an AXL inhibitor in preparation of a medicine for treating heart failure, and relates to the field of pharmacy. The invention provides application of an AXL inhibitor in a medicine for treating heart failure. The AXL inhibitor can remarkably inhibit abnormal activation of fibroblasts and can remarkably improve the heart function of a mouse with heart failure.

The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for imaging cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a patient. The present teachings relate generally to method of making conjugates comprising a fibroblast activation protein (FAP) inhibitor.

The invention provides application of a turbellarian worm extract in preparation of a product for promoting wound healing, a biological agent for promoting the proliferation activity and / or migration ability of fibroblast NIH3T3, a biological agent for improving the wound healing rate and the decrustation time and a biological agent for improving the collagen fiber deposition type in the wound healing process. The biological preparation is used for promoting regeneration of skin appendage organs in the wound healing process. Wherein the extraction of the turbellarian worm extract comprises the steps of turbellarian worm cleaning, tissue crushing, alcohol extraction, centrifugal separation and concentration drying. The turbellarian worm extract has good capacity of promoting wound healing, and has the effects of effectively improving skin wound healing efficiency, shortening decrustation time, inhibiting scar formation in the wound healing process, promoting regeneration of skin appendage organs in the wound healing process and the like.

The invention provides an elastin peptide-containing composition as well as a preparation method and application thereof. The elastin peptide-containing composition comprises elastin peptide, camel milk active small molecule peptide and water lily oligopeptide in a mass ratio of 1: (1-3): (1.8-2.5). The elastin peptide, the camel milk active small molecule peptide and the water lily oligopeptide which are obtained through a specific treatment mode are compounded according to a specific proportion, synthesis of aquaporin AQP3 can be promoted, the content of sodium hyaluronate is increased, and the free radical scavenging activity is improved. The composition containing the elastin peptide can quickly and efficiently improve the skin state, repair the skin, delay the skin aging, enhance the skin function and recover the elasticity. The composition containing elastin peptide can promote the proliferation and growth of fibroblasts, improve the cell viability and promote the healing of skin wounds, and is non-toxic to cells.

The invention provides a fibroblast activating protein targeting compound, a nuclide marker of the fibroblast activating protein targeting compound, a pharmaceutical composition containing the fibroblast activating protein targeting compound and application of the fibroblast activating protein targeting compound and the nuclide marker, and relates to the technical field of nuclide drugs. The fibroblast activating protein targeting compound comprises a compound shown as a formula I, and has remarkably enhanced tumor uptake and retention time. The invention also relates to a pharmaceutical composition and a kit containing the targeting compound, and application of the compound in diagnosis or treatment of fibroblast activating protein overexpression diseases. # imgabs0 #

Bispecific molecules that target cancer-associated fibroblasts are provided herein. Methods of treatment comprising administering a pharmaceutical composition comprising a bispecific molecule as described herein are further provided.

The invention discloses photo-thermal controlled-release nitric oxide anti-biofilm hydrogel based on click reaction crosslinking as well as a preparation method and application of the photo-thermal controlled-release nitric oxide anti-biofilm hydrogel based on click reaction crosslinking, the hydrogel is prepared by taking azide group-containing four-arm polyethylene glycol and alkynyl modified hyaluronic acid as matrixes through click chemistry rapid crosslinking under the catalysis of copper-based nanoparticles, the antibacterial biological membrane has remarkable dual anti-biological membrane and anti-inflammatory effects, and can be applied to wound treatment of bacterial biological membrane infection; through a wound surface coating form, under near-infrared light irradiation, copper nanoparticles generate a mild photothermal effect to remove a biological membrane, and Cu < 2 + > is released to promote fibroblast proliferation; nitric oxide can be controllably released, a biological membrane is synergistically eliminated by enhancing lipid peroxidation and destroying a bacterial membrane structure, meanwhile, angiogenesis is promoted, collagen deposition is stimulated, and the wound healing process is accelerated; the invention has the functions of efficient antibiosis and tissue regeneration, and has wide clinical application prospect and development value in the field of infectious wound treatment.

The invention discloses a lung adenocarcinoma prognosis risk prediction model and a construction method and application thereof, and belongs to the technical field of biomedical detection. The lung adenocarcinoma (LUAD) prognosis model is successfully constructed by systematically analyzing the immune infiltration related gene (CAFRG) of tumor-associated fibroblasts (CAF), and the application value of the lung adenocarcinoma (LUAD) prognosis model in prediction of patient prognosis is verified. The CAFRG risk score is negatively related to the immune microenvironment score and is remarkably related to immune checkpoint gene expression, which suggests that a high-risk patient may have the characteristic of immune escape. Furthermore, based on TIDE tool analysis, the patients in the low-risk group have more active T cell immune response. The risk score is also closely related to the sensitivity of antitumor drugs, especially Doramapimod. Therefore, a new theoretical basis is provided for personalized treatment of lung adenocarcinoma, and a new direction is provided for future clinical research.

The invention relates to a double-layer dressing for promoting wound healing and inhibiting scars and a preparation method and application thereof.The double-layer dressing comprises a hydrogel layer and a piezoelectric film layer compounded on the hydrogel layer, and the piezoelectric film layer is prepared by mixing an organic piezoelectric material, a ferroelectric material and an organic solvent and then conducting an electrostatic spinning technology; the hydrogel layer is formed by curing a methacrylic anhydride acellular extracellular matrix, methacrylic anhydride catechol chitosan and conductive nanoparticles under the action of a curing agent. The lower skin contact layer of the double-layer dressing is the hydrogel layer, so that the directional growth of fibroblasts is favorably induced; the upper dressing is a piezoelectric material composite ferroelectric material, is beneficial to piezoelectric stimulation re-induction function recovery after final skin repair and guidance of directional growth of wound cells, and has good skin wound induction repair and scar inhibition effects.

The invention belongs to the technical field of battery dressings, and particularly relates to a wearable magnesium battery self-powered dressing for chronic wound healing and a preparation method and application thereof. A flexible conductive carbon cloth coated with a viologen-based covalent organic framework material is used as a battery positive electrode, a magnesium sheet is used as a negative electrode, polyacrylamide hydrogel is used as a solid electrolyte, and the flexible wearable self-powered dressing is assembled. The formed electrode can effectively input electrical stimulation to the wound surface, the dressing can simulate an endogenous electric field in the wound, induce migration of fibroblasts, regulate the immune microenvironment of the wound and inhibit inflammatory response, polyacrylamide is used as gel electrolyte, and the dressing has good hygroscopicity, can absorb exudate at the wound surface and keep a wet healing environment, and can be applied to the wound healing. The chronic wound healing of the rat is effectively promoted. The self-powered dressing prepared by the invention provides a reliable electrotherapy method for chronic wound healing.

The invention relates to the technical field of tumor biomedical engineering and organ chips, in particular to a vascularized gastric cancer organ chip and a preparation method thereof.The chip is composed of an integrated micro-fluidic main body, an annular micro-column array and an optical sealing film, and a central culture cavity is divided into a tumor area and a blood vessel area by micro-columns; the preparation method comprises the following steps: injecting a fibrous protein solution containing human umbilical vein endothelial cells and cancer-related fibroblasts into a vascular region, and adding thrombin for in-situ gelation to form a pre-vascularized network; the method comprises the following steps: mixing a patient-derived gastric cancer organ with a methacrylic acid esterified gelatin pre-polymerized solution, injecting the mixture into a tumor area, and carrying out photo-crosslinking immobilization; culturing for 7-14 days under the dynamic perfusion condition of a mixed culture medium to obtain a three-dimensional gastric cancer organ model containing a capillary network; the method is expected to be used for rapid, low-cost and high-throughput screening of chemotherapy or anti-angiogenesis drugs and accurate prediction of individual curative effects of patients.

The invention discloses a method for establishing a co-culture system of porcine skeletal muscle satellite cells (PSCs) and porcine kidney fibroblasts (PKFs). The method comprises the following steps of: performing in-vitro induction on the PKFs to transdifferentiate into adipocytes, optimizing a process of the method, establishing an optimal PSCs and PKFs co-culture induced differentiation method, and selecting a co-culture proportion. According to the method for in-vitro induction of PKFs transdifferentiation and the co-culture system of PKFs and PSCs established by the invention, the PKFs can replace porcine precursor adipocytes (ADSCs) to serve as a source of seed cells in artificial meat fat, and the period of adipogenesis induced differentiation is shortened; the established PKFs and PSCs co-culture system provides a new two-dimensional model for the artificial snowflake meat; a powerful in-vitro model is provided for deep understanding of intercellular interaction and endocrine and paracrine functions of the skeletal muscle which is a highly heterogeneous tissue.

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.

Disclosed are methods, means, and compositions of matter useful for the stimulation of angiogenesis directly by administration of membrane vesicles, such as fibroblast-derived exosomes, and / or through induction of angiogenic cytokines from blood cells contacted with fibroblast-derived exosomes. The invention provides means of treating conditions in which angiogenesis is beneficial through local or systemic administration of exosomes, including those derived from fibroblasts, wherein the fibroblasts are cultured under basal conditions or conditions of hypoxia. In other embodiments exosomes derived from fibroblasts are utilized to augment endogenous regenerative processes, such as hematopoiesis, angiogenesis and neurogenesis, as well as augment regenerative processes stimulated by administration of exogenous therapeutics such as cells, growth factors, or genes.

The invention discloses an application of 4 '-methylamine baicalein in preparation of an anti-photoaging product. Experimental results show that the 4 '-methylamine baicalein not only has very low toxicity to fibroblasts, but also can remarkably improve the multiplication capacity of the fibroblasts irradiated by the UVB and can remarkably inhibit senescence of the fibroblasts irradiated by the UVB, and the effect of the 4'-methylamine baicalein is remarkably superior to that of baicalein; therefore, at least one of 4 '-methylamine baicalein or pharmaceutically acceptable salts, tautomers, stereoisomers and precursor compounds thereof can be used as an active ingredient for preparing anti-photoaging products, and the compound has important significance and application value especially for solving the photoaging problem generated by UVB phototherapy.

Methods and compositions for treating fibrosis (e.g., cardiac fibrosis), or other conditions associated with inflammation and / or fibrosis are provided. Methods can include administering a nucleic acid encoding a sialic acid-binding immunoglobulin-type lectin 9 (Siglec-9) protein to a subject in need of fibrosis treatment, where the Siglec-9 protein is expressed by the nucleic acid in regulatory T (Treg) cells in the subject. Methods and compositions can include Treg cells that overexpress Siglec-9 to enhance the ability of Treg cells to target cells expressing amine oxidase, copper containing 3 (AOC3), including fibroblasts or myofibroblasts. In some embodiments, the enhanced Treg cells are targeted to myofibroblasts (e.g., cardiac myofibroblasts) with elevated expression of fibrotic genes.

The invention belongs to the field of biological medicine, and particularly relates to application of caffeic acid phenethyl ester to preparation of medicine for treating myopia and a medicine composition of the caffeic acid phenethyl ester. It is found for the first time that phenethyl caffeate can promote collagen synthesis of sclera fibroblasts directly related to myopia, inhibit and slow down ocular axis extension and vitreous cavity length increase of a myopia individual, and can increase sclera thickness, so that the effect of delaying and treating myopia is achieved; the invention provides a new choice for clinically treating myopia, and has a good application prospect.

The invention provides a screening platform for chemotherapy combined anti-tumor natural products and application of the screening platform. PTC has tumor cells, interstitial cells, fibroblasts and immune cells from primary epithelium, is rich in cell components, and has advantages in the aspect of tumor microenvironment simulation. Meanwhile, PTC can reproduce tumor heterogeneity, the culture success rate and clinical consistency can reach 90% or above, and the detection period is within two weeks. And the detection result can be read through AI intelligent software, so that the accuracy can be further improved. The screening period can be shortened, the cost is reduced, and the accuracy is improved; according to the platform, high-throughput screening can be carried out in a short time, and the treatment effect of a chemotherapy drug combined anti-tumor natural product drug scheme can be predicted.

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

The present invention relates to immune cells engineered to express chimeric antigen receptors (CARs) that specifically bind to fibroblast activating proteins (FAPs) for use in the treatment of skeletal muscle fibrosis in muscular dystrophy.

The invention provides a fusion protein for promoting proliferation of hair follicle stem cells as well as a preparation method and application of the fusion protein. The fusion protein is formed by fusion expression of a plurality of collagen structural domains capable of being combined with cell integrin and / or specific structural domains from certain functional proteins screened from collagen XVII and III type collagen. Nucleic acid molecules for coding the fusion protein are subjected to codon optimization and then recombined and stably expressed in escherichia coli to obtain the fusion protein. The fusion protein has excellent performance of promoting proliferation and migration of human hair follicle stem cells and human fibroblasts, can be used for repairing skin and hair follicle tissues and improving resistance of skin and hair follicles, and is suitable for popularization and application in the fields of beauty and skin care, medical equipment, tissue engineering and the like.

Provided is a compound for double targeting of a fibroblast activation protein and an integrin subtype, comprising: (i) a chelating ligand moiety (CL); (ii) a first targeting moiety (BT); and (iii) a second targeting moiety (CY), wherein (i), (ii), and (iii) are fixed, combined, or connected by means of any L; BT is a fibroblast activation protein (FAP)-specific binding ligand structure; CY is an integrin subunit αvβ3 or αvβ6-specific binding ligand structure; L is selected from one or a combination of L1, L2, L3, L4, L5, L6, and L7; L1, L2, L3, L4, L5, L6, and L7 are each independently a key, a monovalent joint, a divalent joint, or a trivalent joint. Also provided are a preparation method for the compound and use thereof.

The invention belongs to the technical field of biological medicine, and particularly relates to recombinant human XVII micromolecular collagen as well as a preparation method and application thereof. According to the invention, a recombinant human XVII type micromolecular collagen (Re-Hcol17) is constructed, and a stable triple helix structure is formed by connecting the 15th collagen domain, the 12th collagen domain, the 5th collagen domain and the 1st collagen domain in series. Experimental results prove that the Re-Hcol17 can significantly promote NIH / 3T3 fibroblast proliferation within the concentration range of 10-100 [mu] g / mL, the effect is better than that of natural human collagen, and extracellular matrix adhesion can be effectively promoted. Through genetic engineering and fermentation process innovation, the bottleneck that the human-derived XVII type collagen is difficult to efficiently express and unstable in structure is broken through, and a foundation is laid for wide application of the human-derived XVII type collagen in the fields of biological medicines and cosmetics.

A conjugate of the formula (I) wherein F is a ligand (radical thereof) that binds fibroblast activation protein alpha (FAPα); L is a functionalized linker that binds with F, A, and X; A is a pharmacokinetic extender that binds or associates or binds with a protein in the blood of an animal; and X is chelator; a method of imaging cancer-associated fibroblasts (CAFs) and activated myofibroblasts in a subject; and a method of treating a disease characterized by upregulation of FAPα, such as cancer, in a subject.

The invention relates to the technical field of biological medicines, in particular to an iRGD targeted and anti-fibrosis small molecule dual-modified exosome as well as a construction method and application thereof. The exosome utilizes the specific binding penetration enhancement effect of iRGD (the amino acid sequence is CRGDKGPDC) and a fibroblast high-expression integrin receptor, so that the enrichment efficiency of the exosome at a focus part is improved; the anti-fibrosis micromolecule Let-7a-5p can inhibit a TGF-beta signal channel by blocking Smad2 / 3 phosphorylation, and the anti-fibrosis micromolecule Let-7a-5p and the anti-fibrosis microRNA carried by the exosome generate a synergistic anti-fibrosis effect; the exosome phospholipid bilayer can also protect Let-7a-5p from enzymolysis and prolong the half-life period, and iRGD modification can reduce the non-targeted uptake rate. An animal model verifies that the double-modified exosome has a good skin fibrosis resisting effect, and side effects such as liver and kidney function damage are not found. The invention provides an effective and safe treatment scheme for resisting skin fibrosis.

The invention discloses a high-strength low-immunoreaction bone bonding material and a preparation and application method thereof. The bone binding material comprises tetracalcium phosphate, serine phosphate, magnesium phosphate and a sodium citrate solution. According to the preparation method, tetracalcium phosphate, phosphoserine, magnesium phosphate powder and a sodium citrate solution are fully mixed and reacted by utilizing a hedging device consisting of a screw injector and a connecting pipe. And extruding the mixed liquid material through a filter membrane to complete the preparation of the bone adhesive material. The bone binding material can be used for preparing bionic sclerotin, binding broken bones in comminuted fractures or smearing the bone binding material to bone gaps, and in the decomposition process, the bone binding material can continuously release magnesium ions, so that the immune environment of early bone repair is regulated and controlled, the bone repair process is accelerated, and bone healing is promoted. Meanwhile, experimental data prove that the bone adhesive material provided by the invention can provide stable supporting strength, has no potential toxicity to fibroblasts, and is good in biocompatibility.

The invention relates to a CD44 receptor and scavenger receptor-A (SR-A) dual-targeting pharmaceutical composition as well as a preparation method and application thereof. According to the invention, a certain proportion of carrier material with CD44 receptor targeting capability is adsorbed on the fatty acid albumin nanoparticles, and the albumin nanoparticles with CD44 receptor and SR-A dual-targeting capability are successfully prepared. The albumin nanoparticles can simultaneously deliver drugs to activated macrophages with high SR-A specificity expression and fibroblasts or tumor cells with high CD44 receptor specificity expression, provide new treatment schemes and ideas for various diseases including tissue fibrosis and tumors, and have great application value in the field of biological medicine.

The present invention relates to a fibroblast activation protein alpha (FAP)-targeting conjugate comprising Formula I: Y-L-X, wherein Y is a chelator or cytotoxic drug, L is a linker, and X is a molecule comprising a cyclic peptide of formula A-[Z-AA1-AA2-AA3-AA4-AA5-AA6-AA7-Z]-B. A is N-terminal structure. B is C-terminal structure, and each of the Z, AA1, AA2, AA3, AA4, AA5, AA6, AA7 is a residue of an amino acid.

The application provides an application of a FAP-targeted CAR-T cell in preparation of a drug for treating cardiac fibrosis in a chronic phase of myocarditis. It is found in the application that FAP-specific CAR-T cells can effectively target cells expressing mouse FAP proteins, and the CAR-T cells can effectively eliminate cells expressing mouse FAP proteins after being activated, the chimeric antigen receptor T cells effectively reduce cardiac fibrosis in a chronic phase of myocarditis in mice, and restore the function after inflammatory injury. The application develops a CAR-T therapy for myocardial fibrosis caused by a chronic phase of myocarditis, and the chimeric antigen receptor T cells expressing a targeted fibroblast activation protein can recognize activated myocardial fibroblasts, and significantly reduce cardiac fibrosis after inflammatory injury and restore the function.